PharVision Advisers’s Wabtec WAB Stock Holding History

PharVision Advisers’s Portfolio WAB Stock Details WAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,195	Closed	-$250K	–	804
2025 Q2	$250K	Buy	+1,195	New	+$230K	0.36%	136

Other funds holding WAB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PharVision Advisers's WAB Position: Q3 2025 in Review

PharVision Advisers sold out of Wabtec (WAB) in Q3 2025, closing a stake of 1,195 shares — an estimated $250K sold.

PharVision Advisers first reported a position in WAB in Q2 2025 and held it in 1 quarter. The position peaked at $250K in Q2 2025. 1,094 funds tracked by Wall St. Rank hold WAB as of Q3 2025.

PharVision Advisers reported no remaining Wabtec position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 1,195 Wabtec shares in Q3 2025, an estimated $250K.
PharVision Advisers first reported a position in Wabtec in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Wabtec position peaked at $250K in Q2 2025.
1,094 funds tracked by Wall St. Rank held Wabtec as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.